Claims
- 1. An isolated nucleic acid molecule comprising (a) a nucleotide sequence that encodes a polypeptide having the amino acid sequence of SEQ ID No. 19; or (b) the full length complement of the nucleotide sequence of (a).
- 2. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID No. 18.
- 3. An isolated nucleic acid sequence consisting of a nucleotide sequence selected from the group consisting of SEQ ID No.: 26, SEQ ID No.: 27 and SEQ ID No.: 28.
- 4. A recombinant vector comprising the nucleotide sequence of claim 1, 2 or 3.
- 5. An isolated genetically engineered host cell comprising the recombinant vector of claim 4.
- 6. An expression vector comprising the nucleotide sequence of claim 1 or 2 operatively associated with a regulatory nucleotide sequence containing transcriptional and translational regulatory information that controls expression of the nucleotide sequence in a host cell.
- 7. An isolated genetically engineered host cell comprising the expression vector of claim 6.
- 8. The isolated genetically engineered host cell of claim 5 or 7 in which the host cell is prokaryotic.
- 9. The isolated genetically engineered host cell of claim 5 or 7 in which the host cell is eukaryotic.
- 10. A method for producing recombinant C100-R, comprising:
- (a) culturing a host cell transformed with the expression vector of claim 6 and which expresses the C100-R; and
- (b) recovering the C100-R product from the cell culture.
- 11. The expression vector of claim 6 which is a fusion protein vector.
- 12. A method for producing recombinant C100-R fusion protein, comprising:
- (a) culturing a host cell transformed with the expression vector of claim 11 and which expresses the C100-R fusion protein; and
- (b) recovering the C100-R fusion protein product from the cell culture.
Parent Case Info
The present application is a continuation-in-part of application Ser. No. 08/114,555, filed Aug. 30, 1993, now U.S. Pat. No. 5,854,392 and is a continuation-in-part of application Ser. No. 07/938,184, filed Aug. 31, 1992, now abandoned, which is incorporated by reference herein in its entirety.
Government Interests
This invention was made with Government support under Contract #RO1 NS 28965 awarded by the National Institutes of Health. Therefore, the government has certain rights in the invention.
Non-Patent Literature Citations (2)
Entry |
Leberer et al. The EMBO Journal 11 (1992) 4815-4824. |
Rudinger In "Peptide Hormones" (Jun. 1976) ed. J.A. Parsons, University Park Press, Baltimore, pp. 1-7. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
114555 |
Aug 1993 |
|